Fradafiban hydrochloride

• CAT Number: I041383
• Molecular Formula: C20H22ClN3O4
• Molecular Weight: 403.86
• Purity: ≥95%
• Synonyms: 2-[(3S,5S)-5-[[4-(4-carbamimidoylphenyl)phenoxy]methyl]-2-oxopyrrolidin-3-yl]acetic acid;hydrochloride
• InChI: InChI=1S/C20H21N3O4.ClH/c21-19(22)14-3-1-12(2-4-14)13-5-7-17(8-6-13)27-11-16-9-15(10-18(24)25)20(26)23-16;/h1-8,15-16H,9-11H2,(H3,21,22)(H,23,26)(H,24,25);1H/t15-,16-;/m0./s1
• InChIKey: IUCGFVXOLDQDRV-MOGJOVFKSA-N
• SMILES: C1C(C(=O)NC1COC2=CC=C(C=C2)C3=CC=C(C=C3)C(=N)N)CC(=O)O.Cl

Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
Fradafiban hydrochloride is a nonpeptide mimetic of the arginine-glycine-aspartic acid recognition sequence. Fradafiban hydrochloride binds with high affinity and selectivity to the human platelet GP IIb/IIIa complex and potently inhibits human platelet aggregation in vitro. Fradafiban hydrochloride reversibly binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM[1].
Fradafiban hydrochloride has only very limited oral activity probably due to its high polarity and thus poor absorption after oral ingestion[1].

Reference

[1]. Müller TH, et al. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997 Aug 19;96(4):1130-8.
 [Content Brief]